Original ResearchPublished 9 October 2026Cytarabine-based mobilisation yields higher CD34+ cell counts than cyclophosphamide regardless of prior daratumumab exposure in multiple myelomaWojciech Szlasa · Artur Borkowski · Monika Mordak-Domagała · Jacek Kwiatkowski · Katarzyna Malesa · Mateusz Sawicki · Jarosław DybkoFrontiers in Oncologydoi 10.3389/fonc.2026.1915658
Original ResearchPublished 8 October 2026Integrated hs-cTnI, global longitudinal strain, and coronary artery calcium for risk stratification of anthracycline-related cardiac dysfunction in multiple myelomaXueshan Zhang · Zongliang YuFrontiers in Cardiovascular Medicinedoi 10.3389/fcvm.2026.1830462
ReviewPublished 7 October 2026The 19S proteasome as a therapeutic target in hematologic malignanciesIdaly M. Olivas · Mayra A. Gonzalez-Henry · Saeedeh Darvishi · Evelyn M. Esparza · Anna M. EiringFrontiers in Cell and Developmental Biologydoi 10.3389/fcell.2026.1918833
ReviewPublished 13 August 2026Functional genomics–guided design of CAR-T and CAR-NK therapies in hematological malignancies: aligning cellular engineering with immune escape and microenvironmental resistanceShiqi Cai · Yang Tan · Qian Yang · Juan HuangFrontiers in Genome Editingdoi 10.3389/fgeed.2026.1878460
Original ResearchPublished 12 June 2026Electrophysiological mechanisms behind the differential cardiotoxicity of chemotherapeutic agents Bortezomib and CarfilzomibDario Melgari · Serena Calamaio · Anthony Frosio · Rachele Prevostini · Alessio Malacrida · Luigi Anastasia · Carlo Pappone · Gabriella Nicolini · Guido Cavaletti · Ilaria RivoltaFrontiers in Drug Discoverydoi 10.3389/fddsv.2026.1774061
Original ResearchPublished 30 April 2026Financial toxicity as logistical and relational burden across the lifespan during autologous transplant preparationSean N. HalpinFrontiers in Cancer Control and Societydoi 10.3389/fcacs.2026.1818523
Mini ReviewPublished 15 April 2026CAR T cell engineering approaches to minimise toxicitiesElizabeth Hogben · Anna Schurich · Charlotte GrahamExperimental Biology and Medicinedoi 10.3389/ebm.2026.11021
EditorialPublished 27 March 2026Editorial: Advances and new horizons in cellular therapies for leukemia and myelomaBhavana Bhatnagar · Srinivas DevarakondaFrontiers in Hematologydoi 10.3389/frhem.2026.1812817
ReviewPublished 23 February 2026The role of necroptosis as a possible therapeutic target in multiple myeloma: the emerging roles of necroptosisDuygu AydemirFrontiers in Hematologydoi 10.3389/frhem.2026.1686097
Original ResearchPublished 30 January 2026Long-term outcomes of hyperbaric oxygen pretreatment in autologous hematopoietic stem cell transplantationVinny Lococo · Maire Okoniewski · Abdalla Shoaib · Leyla Shune · Sunil Abhyankar · Anurag Singh · Dennis Allin · Briha Ansari · Joseph McGuirk · Omar S. Aljitawi · Haitham AbdelhakimFrontiers in Hematologydoi 10.3389/frhem.2026.1733667
Original ResearchPublished 12 January 2026Myeloma patients’ attitudes and perceived burden of treatment administration routes and locations: insights from a pan-European surveyEilidh M. Duncan · Silene ten Seldam · Xavier Leleu · Diane Loening-Martens · Charlotte Pawlyn · Séverine Wollenschneider · Katie Joyner · Kate MorganFrontiers in Hematologydoi 10.3389/frhem.2025.1699930
ReviewPublished 7 January 2026To treat or not to treat: a state-of-the-art overview of smoldering multiple myelomaAyushi Garg · Srinivas DevarakondaFrontiers in Hematologydoi 10.3389/frhem.2025.1706219
